AntriaBio Inc. raises additional $2 million

LOUISVILLE — AntriaBio Inc. (OTCQB: ANTB) this week announced that the company has raised another $2 million through a private placement offering to institutions and accredited investors.

Company officials said in a filing with the Securities and Exchange Commission that the new funds will be used for general corporate purposes and to help fund clinical studies of AB101, a once-a-week basal insulin for the treatment of type 1 and type 2 diabetes.

AntriaBio, headquartered at 1450 Infinite Drive, set up shop in Louisville early last year in hopes of resurrecting AB101, which originally was being developed by shuttered Fort Collins-based company PR Pharmaceuticals Inc.

on Facebook on LinkedIn